/BMY

BMY Stock - Bristol-Myers Squibb Company

Q: What is the analyst price target for BMY?

Analyst price target information is not currently available for BMY.

Q: What is BMY's market cap?

Market capitalization information is not currently available for BMY.

Healthcare|Drug Manufacturers - General|NYSE

$55.92+0.27%

+$0.15 (+0.27%) • Jan 13

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

BUY

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+1.7%upside

Target: $56.87

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for BMY

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.29

52W High$63.33

52W Low$42.52

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$48.30B	$45.01B	$46.16B	$46.38B	$42.52B
Gross Profit	$27.43B	$25.36B	$26.49B	$26.76B	$21.70B
Gross Margin	56.8%	56.3%	57.4%	57.7%	51.0%
Operating Income	$9.66B	$8.47B	$9.27B	$9.54B	$4.49B
Net Income	$-8,948,000,000	$8.03B	$6.33B	$6.99B	$-8,995,000,000
Net Margin	-18.5%	17.8%	13.7%	15.1%	-21.2%
EPS	$-4.41	$3.88	$2.97	$3.15	$-3.98

Company Overview

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

Visit Website

Earnings History & Surprises

BMY

Beat Rate

88%

Last 16 quarters

Avg Surprise

+10.4%

EPS vs Estimate

Beats / Misses

14/1

1 met exactly

Latest EPS

$1.63

Q4 2025

EPS Surprise History

Q1 24

+11.8%

$1.70vs$1.52

Q2 24

+0.2%

$-4.40vs$-4.41

Q3 24

+27.8%

$2.07vs$1.62

Q4 24

+20.8%

$1.80vs$1.49

Q1 25

+13.6%

$1.67vs$1.47

Q2 25

+20.8%

$1.80vs$1.49

Q3 25

+33.9%

$1.46vs$1.09

Q4 25

+7.2%

$1.63vs$1.52

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q4 2026	Oct 29, 2026	—	—	—	—
Q3 2026	Jul 30, 2026	—	—	—	—
Q2 2026	Apr 30, 2026	—	—	—	—
Q1 2026	Feb 5, 2026	$1.65	—	—	—
Q4 2025	Oct 30, 2025	$1.52	$1.63	+7.2%	✓ BEAT
Q3 2025	Jul 31, 2025	$1.09	$1.46	+33.9%	✓ BEAT
Q2 2025	Apr 24, 2025	$1.49	$1.80	+20.8%	✓ BEAT
Q1 2025	Feb 6, 2025	$1.47	$1.67	+13.6%	✓ BEAT
Q4 2024	Oct 31, 2024	$1.49	$1.80	+20.8%	✓ BEAT
Q3 2024	Jul 26, 2024	$1.62	$2.07	+27.8%	✓ BEAT
Q2 2024	Apr 25, 2024	$-4.41	$-4.40	+0.2%	✓ BEAT
Q1 2024	Feb 2, 2024	$1.52	$1.70	+11.8%	✓ BEAT
Q4 2023	Oct 26, 2023	$1.76	$2.00	+13.6%	✓ BEAT
Q3 2023	Jul 27, 2023	$1.99	$1.75	-12.1%	✗ MISS
Q2 2023	Apr 27, 2023	$1.98	$2.05	+3.5%	✓ BEAT
Q1 2023	Feb 2, 2023	$1.71	$1.82	+6.4%	✓ BEAT
Q4 2022	Oct 25, 2022	$1.83	$1.99	+8.7%	✓ BEAT
Q3 2022	Jul 27, 2022	$1.79	$1.93	+7.8%	✓ BEAT
Q2 2022	Apr 29, 2022	$1.92	$1.96	+2.1%	✓ BEAT
Q1 2022	Feb 4, 2022	$1.83	$1.83	0.0%	= MET

Frequently Asked Questions about BMY

What is BMY's current stock price?

Bristol-Myers Squibb Company (BMY) is currently trading at $55.92 per share. The stock has moved +0.27% today.

What is the analyst price target for BMY?

The average analyst price target for BMY is $56.88, based on 1 analyst.

What sector is Bristol-Myers Squibb Company in?

Bristol-Myers Squibb Company operates in the Healthcare sector, specifically within the Drug Manufacturers - General industry. The company is traded on the NYSE exchange.

What is BMY's market cap?

Bristol-Myers Squibb Company has a market capitalization of $113.84 billion, making it a large-cap company.

Does BMY pay dividends?

No, Bristol-Myers Squibb Company does not currently pay a dividend to shareholders.